Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do small RNAs interfere with LINE-1?

Harris S Soifer1

  • 1Beckman Research Institute of the City of Hope, Duarte, CA 91010-3011, USA.

Journal of Biomedicine & Biotechnology
|August 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026
Same author

Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.

The Lancet. Oncology·2024
Same author

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.

Cancer research·2023
Same author

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

The lancet. Gastroenterology & hepatology·2021

The RNA interference (RNAi) machinery is crucial for controlling transposable elements in many organisms. This review explores RNAi

Area of Science:

  • Genomics
  • Molecular Biology
  • Epigenetics

Background:

  • Long interspersed elements (LINE-1 or L1) are highly active transposable elements in the human genome.
  • Uncontrolled L1 activity can lead to genomic instability and negative impacts.
  • The RNA interference (RNAi) pathway is known to suppress transposon activity in lower eukaryotes.

Purpose of the Study:

  • To review evidence for RNAi's role in suppressing transposable elements in eukaryotes.
  • To investigate the potential role of RNAi in restricting LINE-1 activity in the human genome.
  • To explore the existence and function of L1-derived small interfering RNAs (siRNAs) in humans.

Main Methods:

  • Review of existing literature on RNAi and transposable elements.
  • Analysis of experimental evidence from various eukaryotic systems.

Related Experiment Videos

  • Speculative analysis based on current understanding of RNAi and L1 biology.

    • Main Results:

    • Substantial evidence demonstrates RNAi's role in controlling transposon activity in lower eukaryotes.
    • Experimental evidence for L1-derived siRNAs and RNAi's role in human LINE-1 restriction is currently lacking.
    • The review consolidates findings from diverse eukaryotic systems to inform the human context.

    Conclusions:

    • RNAi is a critical defense mechanism against transposable elements in many species.
    • Further research is needed to elucidate the specific role of RNAi in regulating human LINE-1 activity.
    • Understanding this interplay is vital for maintaining human genome integrity.